This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

I-MAK's Tahir Amin presses US Congress on effect of patents on drug prices

By Nick Robertson ( November 12, 2025, 23:28 GMT | Comment) -- Tahir Amin, CEO of the IP advocacy group Initiative for Medicines, Access, and Knowledge, is urging lawmakers to examine how patent practices such as evergreening and thickets drive up drug costs. While critics challenge I-MAK’s data, Amin says transparency and debate are necessary to change patent policy to encourage competition.While the national conversation over prescription drug prices has dominated political campaigns, Tahir Amin says he wants to help lawmakers examine how patent policy impacts those costs....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections